NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most sign ...

CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated in an ...

RCGP chair Victoria Tzortziou Brown talks access; and Dr Keith Hopcroft discusses a report that suggests GPs are not following heart failure referral guidance.

Ozelle, a global innovator in intelligent diagnostics, will showcase its next-generation solution at WHX Labs Dubai 2026 (Feb ...

Among India's 89.8 million people with T2D [1], heart failure incidence reaches approximately 50%, with 33% higher ...

CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the ...

A collaborative study from the MRC Laboratory of Medical Sciences (LMS) and Imperial College London has found that the protein ACE2 may play a ...

Orphai Therapeutics Inc. (“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for ...

Background Aortic stenosis (AS) frequently coexists with heart failure (HF), but its prevalence, prognostic impact and management across the full HF spectrum remain incompletely characterised. Methods ...

Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is ...

A new study published in the journal of Medicine showed that both linagliptin and dapagliflozin have good safety profiles and ...